Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van Sells 1,314 Shares of Stock

Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van sold 1,314 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the transaction, the executive vice president now directly owns 2,171 shares in the company, valued at $545,572.30. The trade was a 37.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Laboratory Co. of America Price Performance

Shares of NYSE:LH opened at $247.89 on Friday. The firm has a market capitalization of $20.73 billion, a PE ratio of 28.11, a P/E/G ratio of 1.71 and a beta of 1.07. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average price of $240.74 and a two-hundred day moving average price of $232.44. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $258.59.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Equities analysts forecast that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.16%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 32.65%.

Institutional Trading of Laboratory Co. of America

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital City Trust Co. FL increased its position in shares of Laboratory Co. of America by 1.5% during the fourth quarter. Capital City Trust Co. FL now owns 15,553 shares of the medical research company’s stock valued at $3,567,000 after buying an additional 223 shares during the period. OneDigital Investment Advisors LLC grew its stake in Laboratory Co. of America by 115.7% during the third quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company’s stock valued at $1,361,000 after acquiring an additional 3,265 shares in the last quarter. Alexander Randolph Advisory Inc. purchased a new position in Laboratory Co. of America during the third quarter valued at approximately $955,000. Wealthcare Advisory Partners LLC increased its holdings in Laboratory Co. of America by 23.9% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company’s stock worth $583,000 after acquiring an additional 490 shares during the period. Finally, Mutual of America Capital Management LLC purchased a new stake in Laboratory Co. of America in the 3rd quarter worth approximately $2,316,000. 95.94% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on LH. Morgan Stanley lifted their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. UBS Group dropped their price target on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Bank of America upped their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Barclays decreased their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a research report on Friday, February 7th. Finally, Piper Sandler boosted their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $265.75.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.